新辅助联合辅助达拉非尼和曲美替尼对比标准治疗用于高危可手术切除黑色素瘤:单中心开放随机2期试验
这项单中心开放随机2期试验纳入临床III期或寡转移IV期BRAF V600E/K突变可手术黑色素瘤患者,按1:2随机分配至标准治疗组(先手术,考虑辅助治疗)或新辅助联合辅助达拉非尼和曲美替尼组。预设中期安全性分析显示联合治疗组无事件生存显著延长,试验提前终止。联合治疗耐受良好,无4级不良事件或治疗相关死亡。
要点
- 新辅助联合辅助达拉非尼和曲美替尼显著改善高危可手术黑色素瘤的无事件生存。
- 联合治疗耐受良好,常见不良事件为1-2级寒战、头痛和发热。
核心结论
- 新辅助联合辅助达拉非尼和曲美替尼对比标准治疗显著改善高危可手术切除临床III-IV期黑色素瘤的无事件生存。
- 尽管试验提前终止限制结果普遍性,但结果提供概念验证,支持进一步研究新辅助治疗。
研究设计与样本
- 单中心、开放标签、随机2期试验,在德克萨斯大学MD安德森癌症中心开展。
- 纳入成年(≥18岁)组织学或细胞学确认的可手术切除临床III期或寡转移IV期BRAF V600E或V600K突变黑色素瘤患者。
- 患者按1:2随机分配至标准治疗组(先手术并考虑辅助治疗)或新辅助联合辅助达拉非尼和曲美替尼组(新辅助8周口服达拉非尼150 mg每日两次和曲美替尼2 mg每日一次,术后1周开始辅助治疗至多44周,总计52周)。
- 随机按疾病分期分层,主要终点为意向治疗人群12个月研究者评估的无事件生存。
主要发现
- 预设中期安全性分析(累积四分之一参与者后)显示联合治疗组无事件生存显著更长,试验提前终止。
临床怎么用
- 对于高危可手术切除临床III-IV期BRAF V600E/K突变黑色素瘤,新辅助联合辅助达拉非尼和曲美替尼可能改善无事件生存。
- 治疗前应确认BRAF V600E或V600K突变状态及可手术切除性。
- 新辅助治疗期间需监测不良事件,常见1-2级寒战、头痛和发热,3级腹泻需关注。
局限性
- 试验因中期分析显示显著获益而提前终止,可能高估效应量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dual BRAF and MEK inhibition produces a response in a large number of patients with stage IV BRAF-mutant melanoma. The existing standard of care for patients with clinical stage III melanoma is upfront surgery and consideration for adjuvant therapy, which is insufficient to cure most patients. Neoadjuvant targeted therapy with BRAF and MEK inhibitors (such as dabrafenib and trametinib) might provide clinical benefit in this high-risk p opulation. METHODS: We undertook this single-centre, open-label, randomised phase 2 trial at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Eligible participants were adult patients (aged ≥18 years) with histologically or cytologically confirmed surgically resectable clinical stage III or oligometastatic stage IV BRAFV600E or BRAFV600K (ie, Val600Glu or Val600Lys)-mutated melanoma. Eligible patients had to have an Eastern Cooperative Oncology Group performance status of 0 or 1, a life expectancy of more than 3 years, and no previous exposure to BRAF or MEK inhibitors. Exclusion criteria included metastases to bone, brain, or other sites where complete surgical excision was in doubt. We randomly assigned patients (1:2) to either upfront surgery and consideration for adjuvant therapy (standard of care group) or neoadjuvant plus adjuvant dabrafenib and trametinib (8 weeks of neoadjuvant oral dabrafenib 150 mg twice per day and oral trametinib 2 mg per day followed by surgery, then up to 44 weeks of adjuvant dabrafenib plus trametinib starting 1 week after surgery for a total of 52 weeks of treatment). Randomisation was not masked and was implemented by the clinical trial conduct website maintained by the trial centre. Patients were stratified by disease stage. The primary endpoint was investigator-assessed event-free survival (ie, patients who were alive without disease progression) at 12 months in the intent-to-treat population. This trial is registered at ClinicalTrials.gov, number NCT02231775. FINDINGS: Between Oct 23, 2014, and April 13, 2016, we randomly assigned seven patients to standard of care, and 14 to neoadjuvant plus adjuvant dabrafenib and trametinib. The trial was stopped early after a prespecified interim safety analysis that occurred after a quarter of the participants had been accrued revealed significantly longer event-free survival with neoadjuvant plus adjuvant dabrafenib and trametinib than with standard of care. After a median follow-up of 18·6 months (IQR 14·6-23·1), significantly more patients receiving neoadjuvant plus adjuvant dabrafenib and trametinib were alive without disease progression than those receiving standard of care (ten [71%] of 14 patients vs none of seven in the standard of care group; median event-free survival was 19·7 months [16·2-not estimable] vs 2·9 months [95% CI 1·7-not estimable]; hazard ratio 0·016, 95% CI 0·00012-0·14, p<0·0001). Neoadjuvant plus adjuvant dabrafenib and trametinib were well tolerated with no occurrence of grade 4 adverse events or treatment-related deaths. The most common adverse events in the neoadjuvant plus adjuvant dabrafenib and trametinib group were expected grade 1-2 toxicities including chills (12 patients [92%]), headache (12 [92%]), and pyrexia (ten [77%]). The most common grade 3 adverse event was diarrhoea (two patients [15%]). INTERPRETATION: Neoadjuvant plus adjuvant dabrafenib and trametinib significantly improved event-free survival versus standard of care in patients with high-risk, surgically resectable, clinical stage III-IV melanoma. Although the trial finished early, limiting generalisability of the results, the findings provide proof-of-concept and support the rationale for further investigation of neoadjuvant approaches in this disease. This trial is currently continuing accrual as a single-arm study of neoadjuvant plus adjuvant dabrafenib and trametinib. FUNDING: Novartis Pharmaceuticals Corporation.
引用
- Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018. PMID: 29361468. doi:10.1016/S1470-2045(18)30015-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。